News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

How the FDA Stifles New Cures, Part II: 90% of Clinical Trial Costs are Incurred in Phase III



4/26/2012 8:11:04 AM

Yesterday, the Manhattan Institute released a study I authored, entitled “Stifling New Cures: The True Cost of Lengthy Clinical Drug Trials.” (You can read the full report here.) The paper discusses how outdated FDA policies are making drug development too expensive and too risky. In this excerpt, I detail why late-stage Phase III trials account for 90 percent of the cost of clinical trials in drug development.

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES